CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 75-95% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

SIGA Announces Retirement of Chief Scientific Officer Dennis Hruby, Ph.D.

By GlobeNewswire

NEW YORK, Nov. 09, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies (NASDAQ: SIGA), a commercial stage pharmaceutical company, announced today that Dennis Hruby, Ph.D., Executive Vice President and Chief Scientific Officer, will retire effective today, concluding more than 30 years with the Company.

Dr. Hruby joined SIGA in 1996 as a senior scientific advisor, became Vice President of Research in 1997, and has served as Chief Scientific Officer since 2000. Over that period, he led the development of tecovirimat, now marketed as TPOXX®, from early-stage research through U.S. FDA approval of the oral formulation in 2018 and the intravenous formulation in 2022, as well as regulatory approvals in Canada, the European Union, the United Kingdom and Japan. TPOXX was the first antiviral therapeutic approved for the treatment of smallpox and has been sold to more than 30 countries.

“Dennis Hruby's 30 years of service reflect a distinguished career defined by scientific rigor, vision, and an unwavering commitment to public health. As a foremost expert in infectious disease, he played an instrumental role in the development of TPOXX, a medical countermeasure that has fundamentally strengthened our nation's preparedness against smallpox,” said Diem Nguyen, Chief Executive Officer. “On behalf of everyone at SIGA whose work he shaped, I want to thank Dennis for his extraordinary contributions and wish him well in the exciting chapter ahead.”

“I’m so proud of what we built at SIGA. When I joined, there was no antiviral treatment for smallpox. There is one now, and it is approved, stockpiled, and ready if ever needed to help save lives,” said Dr. Hruby. “I'm leaving the rest to a strong, successful team, and I look forward to seeing what comes next.”

Following his retirement, Dr. Hruby will continue to support the Company in an advisory capacity.

ABOUT SIGA
SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on smallpox, we are dedicated to protecting humanity against the world’s most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. For more information about SIGA, visit www.siga.com.

Investor and Media Contact
Suzanne Harnett
sharnett@siga.com


Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.